SITC Scientific Publications News

In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading ...
0 comments
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a comprehensive summary on the Surrogate Endpoints Virtual Summit , which was held on April 5, 2024. Surrogate endpoints have been instrumental for the advancement of immunotherapy, including dozens of approvals for a multitude of modalities across various disease states. These approvals are often facilitated through the use of endpoints that serve as surrogates ...
0 comments
On behalf of the SITC Board of Directors, we are pleased to announce the publication of a new manuscript titled, “ Challenges and Opportunities in Cancer Immunotherapy: A Society for Immunotherapy of Cancer (SITC) Strategic Vision ” available now in the Journal for ImmunoTherapy of Cancer (JITC) . This manuscript is the first in a JITC Special Series — The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer ...
0 comments
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the ...
0 comments
On behalf of the Society for Immunotherapy of Cancer (SITC) and in collaboration with the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP), we are pleased to announce the publication of a new manuscript titled " Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society ...
0 comments
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading ...
0 comments
On behalf of the Society for Immunotherapy of Cancer (SITC), the SITC Biomarkers Committee, the SITC Pathology Committee, and the 2024 SITC Clinical Immuno-Oncology Network ( SCION ) faculty, we are pleased to announce the publication of a commentary on measurement and interpretation of essential biomarkers in early clinical trials . Immunotherapy of cancer is now a mainstay of modern oncologic practice and is being integrated with conventional ...
0 comments
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading ...
0 comments
On behalf of the society and the SITC Intratumoral Immunotherapy Clinical Trials Manuscript Development Group, we are pleased to announce the publication of a new manuscript “ Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease ” in the Journal for ImmunoTherapy of Cancer . While intratumoral immunotherapies have the potential to boost anti-tumor ...
0 comments
Dr. Michael T. Lotze is Incoming Editor-in-Chief for the Journal for ImmunoTherapy of Cancer ( JITC ). As he transitions into his role with JITC , learn more about Dr. Lotze’s career, interest in JITC , and personal life. Career What inspired you to become a researcher? Dr. Lotze: My earliest experiences in research were a disaster; I worked on a project at Northwestern University over the summer after ...
0 comments
SITC 2024 Advances in Cancer Immunotherapy Series We’re excited to announce SITC’s 2024 Advances in Cancer Immunotherapy (ACI) educational series, which offers in-depth clinical training in immunotherapy treatment for a variety of disease states and topics from experts in the field. The ACI programs aim to engage practicing clinical oncologists, advanced practitioners, nurses, pharmacists, emergency physicians, and other allied health professionals ...
0 comments
On behalf of the Society for Immunotherapy of Cancer (SITC) and the SITC Melanoma Guideline Expert Panel, we are pleased to announce the publication of SITC’s Melanoma Clinical Practice Guideline (CPG), version 3.0. This manuscript is SITC’s first CPG covering immunotherapy indications for cutaneous melanoma as well as rarer subtypes of the disease. Immunotherapy is a standard of care option for both BRAF -wildtype and BRAFV600 -mutated ...
0 comments
On behalf of the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG), we are pleased to announce the publication of the “ Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group ,” in the Journal of Clinical Oncology. These recommendations provide a detailed clinical trial design guide ...
0 comments
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading ...
0 comments
On behalf of the Society for Immunotherapy of Cancer (SITC) and the SITC Gynecologic Cancer Immunotherapy Guideline Expert Panel, we are pleased to announce the publication of SITC’s Gynecologic Cancer Clinical Practice Guideline (CPG). This manuscript is SITC’s first CPG covering immunotherapy indications for cervical, endometrial, and ovarian cancer, as well as other rare gynecologic cancers. The treatment landscape in gynecologic cancers is ...
0 comments
SITC is pleased to announce the publication of our newest guideline, " Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. " Clinicians will find this guideline an invaluable resource to assist in navigating the challenging issues that sometimes arise during the treatment of gastrointestinal cancer, including treatment selection based on histology and biomarker status, ...
0 comments
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid tumors, providing deep and durable responses for many patients. However, the anti-tumor mechanism of action of ICIs can also cause aberrantly active self-damaging immune responses, leading to immune-related adverse events (irAEs). The natural history, response to treatment, and patterns of irAEs vary widely, ranging from short-term inflammatory conditions to prolonged ...
0 comments
The Society for Immunotherapy of Cancer (SITC) hosted the "Combination Immunotherapy Resistance Workshop" with the purpose of bringing together immunotherapy experts from across academia, government, and industry to reach consensus on definitions of IO resistance to accelerate drug development. Consensus resistance definitions from the workshop have recently been published in the Journal for ImmunoTherapy of Cancer ( JITC ) via three manuscripts, ...
0 comments
JITC is proud to announce the first publications in a new series, “Liquid Biopsies Coming of Age: Biology, Emerging Technologies, and Clinical Translation.” Authored by leading voices in cancer biology, technology development, and immuno-oncology, this JITC series features authoritative review articles on liquid biopsy- and ctDNA-related uses in immuno-oncology, with accompanying clinically-focused viewpoint letters from expert physicians. ...
0 comments
JITC’s complete special series of review articles, Imaging and Immunotherapy, is now available. Edited by Elisabeth G.E. de Vries, MD, PhD, and Lawrence H. Schwartz, MD, and authored by leading voices from a multitude of backgrounds, this series explores novel imaging strategies, new approaches to conventional imaging – including the use of artificial intelligence, radiomics, and MRI – and special considerations for radiotherapy, immunotherapy, ...
0 comments